Paper32196334
Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.
Winn BA and 15 others. J Nat Prod, 2020. Cited by 19 papers, by iCite.
Cite this record
ConductScience Library. Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia. Papers, record 32196334. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32196334
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents, Phytogenic | Major topic |
| Prodrugs | Major topic |
| Stilbenes | Major topic |
| A549 Cells | |
| Animals | |
| Breast Neoplasms | |
| Cell Hypoxia | |
| Colchicine | |
| Drug Screening Assays, Antitumor | |
| Female | |
| Humans | |
| Mice | |
| Mice, Inbred BALB C | |
| NADPH-Ferrihemoprotein Reductase | |
| Tubulin |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA140674 | NCI NIH HHS | United States | R01CA140674 | PubMed and NIH | NIH RePORTER |
| S10 RR024757 | NCRR NIH HHS | United States | S10RR024757 | PubMed and NIH | NIH RePORTER |
| P30 CA142543 | NCI NIH HHS | United States | P30CA142543 | PubMed and NIH | NIH RePORTER |
| HHSN261200800001C | CCR NIH HHS | United States | PubMed | PubMed | |
| HHSN261200800001E | NCI NIH HHS | United States | PubMed | PubMed |
References62
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 486895 | Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. | Br J Radiol | 1979 | https://conductscience.org/library/papers/486895 | PubMed |
| 2 | 21321746 | A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment. | Integr Biol (Camb) | 2011 | https://conductscience.org/library/papers/21321746 | PubMed |
| 3 | 12956893 | Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases. | J Pharm Pharmacol | 2003 | https://conductscience.org/library/papers/12956893 | PubMed |
| 4 | 25264827 | Biological evaluation of the activity of some benzimidazole-4,7-dione derivatives. | Molecules | 2014 | https://conductscience.org/library/papers/25264827 | PubMed |
| 5 | 2920809 | Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. | Experientia | 1989 | https://conductscience.org/library/papers/2920809 | PubMed |
| 6 | 3412321 | Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. | Mol Pharmacol | 1988 | https://conductscience.org/library/papers/3412321 | PubMed |
| 7 | 20570444 | The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. | Cancer Treat Rev | 2011 | https://conductscience.org/library/papers/20570444 | PubMed |
| 8 | 23149893 | Imaging hypoxia to improve radiotherapy outcome. | Nat Rev Clin Oncol | 2012 | https://conductscience.org/library/papers/23149893 | PubMed |
| 9 | 19125622 | Tubulin-interactive natural products as anticancer agents. | J Nat Prod | 2009 | https://conductscience.org/library/papers/19125622 | PubMed |
| 10 | 22937031 | Tubulin-destabilizing agent BPR0L075 induces vascular-disruption in human breast cancer mammary fat pad xenografts. | PLoS One | 2012 | https://conductscience.org/library/papers/22937031 | PubMed |
| 11 | 17406391 | Sulforhodamine B colorimetric assay for cytotoxicity screening. | Nat Protoc | 2006 | https://conductscience.org/library/papers/17406391 | PubMed |
| 12 | 7752190 | Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a) | J Med Chem | 1995 | https://conductscience.org/library/papers/7752190 | PubMed |
| 13 | 22235096 | Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22235096 | PubMed |
| 14 | 9572894 | Antineoplastic agents. 379. Synthesis of phenstatin phosphate. | J Med Chem | 1998 | https://conductscience.org/library/papers/9572894 | PubMed |
| 15 | 10682679 | NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line. | Br J Cancer | 2000 | https://conductscience.org/library/papers/10682679 | PubMed |
| 16 | 15928673 | Disrupting tumour blood vessels. | Nat Rev Cancer | 2005 | https://conductscience.org/library/papers/15928673 | PubMed |
| 17 | 17459681 | Vascular damaging agents. | Clin Oncol (R Coll Radiol) | 2007 | https://conductscience.org/library/papers/17459681 | PubMed |
| 18 | 9537252 | Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. | Cancer Res | 1998 | https://conductscience.org/library/papers/9537252 | PubMed |
| 19 | 10893310 | Antineoplastic agents. 443. Synthesis of the cancer cell growth inhibitor hydroxyphenstatin and its sodium diphosphate prodrug. | J Med Chem | 2000 | https://conductscience.org/library/papers/10893310 | PubMed |
| 20 | 14505799 | 3-substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: mechanism of activation and cytotoxicity in vitro. | Biochem Pharmacol | 2003 | https://conductscience.org/library/papers/14505799 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42792253 | Engineering a Redox-Responsive Bimolecular Prodrug for Targeted Gastric Cancer Combination Therapy: Design, Synthesis, and In Vivo Evaluation. | Antioxidants (Basel) | 2026 | https://conductscience.org/library/papers/42792253 | PubMed |
| 40927638 | Targeting Tumor-Associated Hypoxia with Bioreductively Activatable Prodrug Conjugates Derived from Dihydronaphthalene, Benzosuberene, and Indole-based Inhibitors of Tubulin Polymerization. | RSC Med Chem | 2025 | https://conductscience.org/library/papers/40927638 | PubMed |
| 40535125 | Research progress on the cross-regulation between ferroptosis and immunogenic cell death in tumor micro-environment. | Front Oncol | 2025 | https://conductscience.org/library/papers/40535125 | PubMed |
| 39124883 | Recent Advances in the Application of Nitro(het)aromatic Compounds for Treating and/or Fluorescent Imaging of Tumor Hypoxia. | Molecules | 2024 | https://conductscience.org/library/papers/39124883 | PubMed |
| 38026524 | Preparation and Characterization Evaluation of Poly(L-Glutamic Acid)-g-Methoxy Poly(Ethylene Glycol)/Combretastatin A4/BLZ945 Nanoparticles for Cervical Cancer Therapy. | Int J Nanomedicine | 2023 | https://conductscience.org/library/papers/38026524 | PubMed |
| 37984295 | Synthesis and biological evaluation of structurally diverse 6-aryl-3-aroyl-indole analogues as inhibitors of tubulin polymerization. | Eur J Med Chem | 2024 | https://conductscience.org/library/papers/37984295 | PubMed |
| 36077745 | Demonstrating Tumor Vascular Disrupting Activity of the Small-Molecule Dihydronaphthalene Tubulin-Binding Agent OXi6196 as a Potential Therapeutic for Cancer Treatment. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36077745 | PubMed |
| 35295719 | Microtubule Organization Is Essential for Maintaining Cellular Morphology and Function. | Oxid Med Cell Longev | 2022 | https://conductscience.org/library/papers/35295719 | PubMed |
| 35215299 | Nitroaromatic Hypoxia-Activated Prodrugs for Cancer Therapy. | Pharmaceuticals (Basel) | 2022 | https://conductscience.org/library/papers/35215299 | PubMed |
| 34638255 | Imaging-Guided Evaluation of the Novel Small-Molecule Benzosuberene Tubulin-Binding Agent KGP265 as a Potential Therapeutic Agent for Cancer Treatment. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34638255 | PubMed |
| 34326502 | Therapeutic targeting of the hypoxic tumour microenvironment. | Nat Rev Clin Oncol | 2021 | https://conductscience.org/library/papers/34326502 | PubMed |
| 33925707 | Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors. | Molecules | 2021 | https://conductscience.org/library/papers/33925707 | PubMed |
| 33262127 | Preclinical Applications of Multi-Platform Imaging in Animal Models of Cancer. | Cancer Res | 2021 | https://conductscience.org/library/papers/33262127 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CA4 | 762 | PubTator's text mining | https://conductscience.org/library/genes/762 | NCBI Gene |
| POR | 5447 | PubTator's text mining | https://conductscience.org/library/genes/5447 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32196334
GET https://conductscience.org/api/papers/v1/32196334/references?page=2